Drug Details
General Information of the Drug (ID: DR0258) | ||||
---|---|---|---|---|
Name |
Flutamide
|
|||
Synonyms |
Apimid; ApoFlutamide; Cebatrol; Chimax; Cytamid; Drogenil; Eulexin; Eulexine; Fluken; Flulem; Flumid; FlutaGRY; Flutacell; Flutamida; Flutamidum; Flutamin; Flutandrona; Flutaplex; Flutexin; Fugerel; METHOXYCHLOR; NFBA; Niftholide; Niftolid; Niftolide; NovoFlutamide; Odyne; Oncosal; Prostacur; Prostandril; Prostica; Prostogenat; Testotard; Alphapharm Brand of Flutamide; Apo Flutamide; Apogepha Brand of Flutamide; Apotex Brand of Flutamide; Azupharma Brand of Flutamide; Cell pharm Brand of Flutamide; Chephasaar Brand of Flutamide; Chiron Brand of Flutamide; Ciclum Brand of Flutamide; Esparma Brand of Flutamide; Essex Brand of Flutamide; Fluta GRY; Fluta cell; Gry Brand of Flutamide; Hexal Brand of Flutamide; InibsaBrand of Flutamide; Ipsen Brand of Flutamide; Juta Brand of Flutamide; Kendrick Brand of Flutamide; Lemery Brand of Flutamide; Novo Flutamide; Novopharm Brand of Flutamide; PMS Flutamide; Pharmascience Brand of Flutamide; Prasfarma Brand of Flutamide; Q Pharm Brand of Flutamide; Schering Brand of Flutamide; Schering Plough Brand of Flutamide; TAD Brand of Flutamide; Tedec Meiji Brand of Flutamide; F 9397; F0663; Fluta 1A Pharma; Flutamide USP25; SCH13521; Sch 13521; Apo-Flutamide; Cebatrol, veterinary; Eulexin (TN); Fluta-GRY; Fluta-cell; Flutamida [INN-Spanish]; Flutamide(pubertal study); Flutamidum [INN-Latin]; NK-601; Novo-Flutamide; PMS-Flutamide; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; Q-Pharm Brand of Flutamide; Sch-13521; Schering-Plough Brand of Flutamide; Flutamide [USAN:BAN:INN]; Ham's F-12 medium; Eulexin, Flutamin, Drogenil,Flutamide; Flutamide (JAN/USP/INN); Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; M-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; M-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-(8CI); 1A Brand of Flutamide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; 4'-Nitro-3'-trifluoromethylisobutyramilide; 4'-Nitro-3'-trifluoromethylisobutyranilide; 4-Nitro-3-(trifluoromethyl)isobutyranilide; Flutamide (AR inhibitor)
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Prostate cancer [ICD-11: 2C82] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C11H11F3N2O3
|
|||
PubChem CID | ||||
Canonical SMILES |
CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F
|
|||
InChI |
1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
|
|||
InChIKey |
MKXKFYHWDHIYRV-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 13311-84-7
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Resveratrol | Gnetum parvifolium | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | AR | Molecule Info |
Pathway MAP
|
|
In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
The combination of resveratrol with flutamide had a synergistic effect on down-regulation of androgen receptor (AR). |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Androgen receptor (AR) | Molecule Info | [3] | |
KEGG Pathway | Oocyte meiosis | Click to Show/Hide | ||
2 | Pathways in cancer | |||
3 | Prostate cancer | |||
NetPath Pathway | EGFR1 Signaling Pathway | Click to Show/Hide | ||
2 | AndrogenReceptor Signaling Pathway | |||
3 | FSH Signaling Pathway | |||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
2 | Coregulation of Androgen receptor activity | |||
3 | Regulation of Androgen receptor activity | |||
4 | Nongenotropic Androgen signaling | |||
5 | Regulation of nuclear beta catenin signaling and target gene transcription | |||
6 | FOXA1 transcription factor network | |||
7 | Notch-mediated HES/HEY network | |||
Reactome | Nuclear Receptor transcription pathway | Click to Show/Hide | ||
2 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | |||
WikiPathways | SIDS Susceptibility Pathways | Click to Show/Hide | ||
2 | Integrated Pancreatic Cancer Pathway | |||
3 | Prostate Cancer | |||
4 | Integrated Breast Cancer Pathway | |||
5 | Nuclear Receptors | |||
6 | Androgen receptor signaling pathway |